Phio Pharmaceuticals
Phio Pharmaceuticals is a biotechnology company focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) platform. The company aims to silence tumor-induced immune suppression and develop powerful therapeutic compounds to overcome tumor immune escape, providing innovative treatment options beyond current modalities. It is publicly traded on Nasdaq and has recently satisfied Nasdaq listing requirements.
Industries
Nr. of Employees
small (1-50)
Phio Pharmaceuticals
King Of Prussia, Pennsylvania, United States, North America
Patents
Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1
US-11926828-B2
View DetailsRNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US-11667915-B2
View Details
Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1
US-11926828-B2
View DetailsRNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US-11667915-B2
View DetailsProducts
siRNA therapeutic candidate targeting PD-1 (preclinical/clinical transition)
An siRNA therapeutic designed to reduce PD-1 receptor expression in T cells for use in ex vivo cell manufacturing and/or localized intratumoral administration to achieve checkpoint modulation.
siRNA therapeutic candidate targeting TIGIT (preclinical)
An siRNA therapeutic designed to silence TIGIT expression in T cells and NK cells to increase cytotoxic activity against tumors; evaluated for intratumoral delivery and adoptive cell therapy applications.
siRNA therapeutic candidate targeting BRD4 (preclinical)
An siRNA candidate targeting BRD4 intended to modulate T cell differentiation toward effector memory phenotypes to improve persistence and functional responses in immunotherapy contexts.
INTASYL™
INTASYL is a patented platform of self-delivering, chemically modified siRNA compounds designed to silence genes tumors use to evade the immune system, adaptable to intra-tumoral and adoptive cell therapy applications.
INTASYL PH-762
PH-762 is an INTASYL compound that reduces the expression of PD-1, a protein inhibiting T cells' ability to kill cancer cells, targeting cutaneous squamous cell carcinoma, advanced melanoma, Merkel cell carcinoma, metastatic melanoma, head and neck squamous cell carcinoma, and other solid tumors.
INTASYL™ self-delivering RNAi therapeutic dual targeting PD-1 and CTLA-4
A self-delivering RNAi therapeutic platform that provides synergistic antitumor efficacy by dual targeting PD-1 and CTLA-4, administered intratumorally in a murine colon cancer model.
siRNA therapeutic candidate targeting PD-1 (preclinical/clinical transition)
An siRNA therapeutic designed to reduce PD-1 receptor expression in T cells for use in ex vivo cell manufacturing and/or localized intratumoral administration to achieve checkpoint modulation.
siRNA therapeutic candidate targeting TIGIT (preclinical)
An siRNA therapeutic designed to silence TIGIT expression in T cells and NK cells to increase cytotoxic activity against tumors; evaluated for intratumoral delivery and adoptive cell therapy applications.
siRNA therapeutic candidate targeting BRD4 (preclinical)
An siRNA candidate targeting BRD4 intended to modulate T cell differentiation toward effector memory phenotypes to improve persistence and functional responses in immunotherapy contexts.
INTASYL™
INTASYL is a patented platform of self-delivering, chemically modified siRNA compounds designed to silence genes tumors use to evade the immune system, adaptable to intra-tumoral and adoptive cell therapy applications.
INTASYL PH-762
PH-762 is an INTASYL compound that reduces the expression of PD-1, a protein inhibiting T cells' ability to kill cancer cells, targeting cutaneous squamous cell carcinoma, advanced melanoma, Merkel cell carcinoma, metastatic melanoma, head and neck squamous cell carcinoma, and other solid tumors.
INTASYL™ self-delivering RNAi therapeutic dual targeting PD-1 and CTLA-4
A self-delivering RNAi therapeutic platform that provides synergistic antitumor efficacy by dual targeting PD-1 and CTLA-4, administered intratumorally in a murine colon cancer model.
Services
Design and execution of murine tumor model studies to evaluate antitumor activity, mechanism-of-action endpoints, immune infiltration, biomarker changes, and tolerability for siRNA candidates.
Collaborative programs to integrate transient siRNA-based modulation into cell manufacturing workflows to improve immune effector function without permanent genetic modification.
Coordination and execution of preclinical studies and preparatory activities required to support regulatory submissions and early-phase clinical trial initiation.
Formation of collaborative research agreements, option arrangements and licensing partnerships with academic and industry groups to accelerate target discovery and candidate development.
Preparation and delivery of scientific posters, oral presentations and investor webcasts to disseminate preclinical data and company updates at scientific and investor conferences.
Design and execution of murine tumor model studies to evaluate antitumor activity, mechanism-of-action endpoints, immune infiltration, biomarker changes, and tolerability for siRNA candidates.
Collaborative programs to integrate transient siRNA-based modulation into cell manufacturing workflows to improve immune effector function without permanent genetic modification.
Coordination and execution of preclinical studies and preparatory activities required to support regulatory submissions and early-phase clinical trial initiation.
Formation of collaborative research agreements, option arrangements and licensing partnerships with academic and industry groups to accelerate target discovery and candidate development.
Preparation and delivery of scientific posters, oral presentations and investor webcasts to disseminate preclinical data and company updates at scientific and investor conferences.
Expertise Areas
- RNA interference (RNAi) therapeutics
- Immuno-oncology drug development
- Adoptive cell therapy process integration
- Local (intratumoral) therapeutic delivery
Key Technologies
- Self-delivering / delivery-enabled siRNA
- Intratumoral delivery techniques
- Ex vivo immune cell programming
- siRNA-mediated gene silencing of checkpoints and regulatory targets
News & Updates
Phio Pharmaceuticals announced positive data from in vivo studies showing that intratumoral delivery of INTASYL compounds inhibited tumor growth and overcame the immunosuppressive tumor microenvironment, supporting further clinical development.
Phio Pharmaceuticals announced positive data from in vivo studies showing that intratumoral delivery of INTASYL compounds inhibited tumor growth and overcame the immunosuppressive tumor microenvironment, supporting further clinical development.